Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
What This Means
Featuring: Moleculin
June 11, 2025
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
What This Means
Featuring: Veru
May 28, 2025
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
What This Means
Featuring: Palisade Bio
May 27, 2025
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
CEO Connect
Featuring: Autonomix Medical
May 13, 2025
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
What This Means
Featuring: CNS Pharmaceuticals
May 13, 2025
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)
KOL Connect
Featuring: Veru
May 8, 2025
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru
Past Events
New to Virtual Investor
Closing Bell
Closing Bell
Live What This Means
Closing Bell Series
Live What This Means
Closing Bell Series
Closing Bell Series
Closing Bell Series
Past Events
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact